The unique ORS effervescent tablet has been developed according to the latest guidelines of the WHO. It has a substantial marketshare in several countries. We are looking for partners to further expand this success. More
Palau Pharma has developed a small molecule H4 receptor antagonist that is about to enter Phase I clinical trials for the treatment of allergic rhinitis and asthma. More
Kortos® Cream contains anti-inflammatory-antipruritic-vasoconstrictor, astringent, antiseptic and local anesthetic in a special water repellant base. More